Diabetes mellitus due to olanzapine use: A case report; [Olanzapin'e baǧli diabetes mellitus: Bir olgu sunumu]
No Thumbnail Available
Date
2003
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Olanzapine, a serotonin-dopamine-receptor antagonist, is an atypical antipsychotic agent used to treat schizophrenia and other psychotic disorders. It has relatively low frequency of side effects such as sedation, orthostatic hypotension, extrapyramidal symptoms, and anticholinergic side effects. Here, a 32-years-old female patient with schizophrenia who developed diabetes after 3 years of olanzapine treatment is presented. Due to lack of family history and immune marker positivity in the occurrence of diabetes, the condition was attributed to olanzapine treatment. After discontinuation of the treatment DM was improved. Controlled studies are necessary both to elucidate the mechanism by which olanzapine can cause dysregulation of glucose homeostasis, and to develop guidelines for the use of olanzapine in patients with known as well as in patients with risk factors for diabetes.
Description
Keywords
dopamine receptor blocking agent , glucose , olanzapine , serotonin antagonist , adult , article , case report , clinical feature , diabetes mellitus , disease course , extrapyramidal symptom , family history , female , glucose homeostasis , human , orthostatic hypotension , risk factor , schizophrenia , sedation